Trials / Completed
CompletedNCT04573309
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
A Phase 2, Open-label Study to Assess Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This exploratory study will investigate the effects of ALXN1840 on copper balance in participants with Wilson disease (WD).
Detailed description
Participants who are treatment experienced (which includes standard-of-care therapies or ALXN1840) and treatment naïve are eligible for this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALXN1840 | Administered orally as tablets. |
Timeline
- Start date
- 2020-09-07
- Primary completion
- 2022-06-07
- Completion
- 2022-06-07
- First posted
- 2020-10-05
- Last updated
- 2024-06-24
- Results posted
- 2023-10-27
Locations
3 sites across 3 countries: United States, New Zealand, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04573309. Inclusion in this directory is not an endorsement.